Neuronetics Inc (NASDAQ:STIM) VP Peter Donato sold 8,595 shares of Neuronetics stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $14.93, for a total transaction of $128,323.35. The transaction was disclosed in a filing with the SEC, which is available at this link.
Peter Donato also recently made the following trade(s):
- On Friday, May 10th, Peter Donato sold 23,053 shares of Neuronetics stock. The shares were sold at an average price of $15.27, for a total transaction of $352,019.31.
- On Friday, March 8th, Peter Donato sold 26,238 shares of Neuronetics stock. The shares were sold at an average price of $16.15, for a total transaction of $423,743.70.
Neuronetics stock opened at $14.85 on Friday. The company has a market cap of $273.89 million and a PE ratio of -5.52. The company has a current ratio of 8.94, a quick ratio of 8.74 and a debt-to-equity ratio of 0.52. Neuronetics Inc has a 1 year low of $13.26 and a 1 year high of $39.39.
Neuronetics (NASDAQ:STIM) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.05). Neuronetics had a negative net margin of 47.21% and a negative return on equity of 1,385.60%. The company had revenue of $12.73 million for the quarter, compared to the consensus estimate of $12.72 million. As a group, analysts anticipate that Neuronetics Inc will post -1.64 earnings per share for the current fiscal year.
STIM has been the topic of several recent analyst reports. BTIG Research reiterated a “buy” rating and set a $25.00 price objective on shares of Neuronetics in a research report on Wednesday, March 6th. Zacks Investment Research upgraded shares of Neuronetics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. Finally, Piper Jaffray Companies reduced their price objective on shares of Neuronetics from $35.00 to $28.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 5th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $31.60.
Several hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp acquired a new stake in Neuronetics in the third quarter valued at approximately $468,000. BlackRock Inc. raised its stake in shares of Neuronetics by 16,237.6% during the third quarter. BlackRock Inc. now owns 408,440 shares of the company’s stock valued at $13,095,000 after acquiring an additional 405,940 shares during the last quarter. Teachers Advisors LLC bought a new position in shares of Neuronetics during the third quarter valued at $267,000. TIAA CREF Investment Management LLC bought a new position in shares of Neuronetics during the third quarter valued at $285,000. Finally, Vanguard Group Inc. raised its stake in shares of Neuronetics by 1,510.2% during the third quarter. Vanguard Group Inc. now owns 241,533 shares of the company’s stock valued at $7,744,000 after acquiring an additional 226,533 shares during the last quarter. 69.27% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Insider Selling: Neuronetics Inc (STIM) VP Sells 8,595 Shares of Stock” was originally reported by Stock Observer and is the property of of Stock Observer. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.thestockobserver.com/2019/05/17/insider-selling-neuronetics-inc-stim-vp-sells-8595-shares-of-stock.html.
Neuronetics Company Profile
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Further Reading: How Important is Technical Analysis of Stocks
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.